


## Treatments and vaccines agreements over time

### COVID-19 Treatments and Vaccines Manufacturing Agreements



**Data Notes:**

- Based on publicly available information.
- The total number of vaccine partnerships may not represent the total number of active agreements. It is unclear whether all facilities are currently producing vaccines.
- Vaccine partnerships are agreements for vaccine production outsourced to third party organizations.
- Vaccine and treatment partnerships include agreements for candidates that have been discontinued or rejected and yet to be approved.
- Treatment agreements include subsidiaries of parent companies.

**1.** Gilead signs VLAs with 8 manufacturers for Remdesivir production.

**2.** Merck signs VLAs with 8 manufacturers in India for Molnupiravir; Eli Lilly signs VLAs with 8 manufacturers for Baricitinib; 1 additional Remdesivir VLA **signed**.

**3.** 23 manufacturers sign up to manufacture Molnupiravir through the MPP. 37 manufacturers sign up to manufacture Paxlovid through the MPP.

**4.** 7 manufacturers sign up to manufacture Ensitrelvir through the MPP.

The number of agreements shown in **text boxes** only indicates that number of agreements signed in the **time period indicated** by the numbers 1 to 4 on the graph. This **does not include** any **subsequent agreements**, and may not represent the **total number of agreements** signed, nor the number of **active agreements** for any treatment included